Interferon and Interleukin-2 Therapy of Kaposi’s Sarcoma
It is difficult to treat Kaposi’s sarcoma by conventional therapies in the setting of immune deficiency such as the acquired immunodeficiency syndrome (AIDS), because this treatment may cause further immune suppression. In AIDS, cytotoxic chemotherapy may, for example, increase the risk of opportunistic infections such as Pneumocystis pneumonia. Thus, this therapy, even if successful against the tumor, may potentially shorten survival. Because of these factors, experimental therapy with immune modulating agents has been particularly attractive in AIDS-related Kaposi’s sarcoma. The two agents receiving most attention have been recombinant alpha interferon and recombinant interleukin–2. These will be the subject of this review. The results will be preliminary because the disease itself is so new and because many of the clinical trials of these agents are still in progress.
KeywordsOpportunistic Infection Acquire Immunodeficiency Syndrome Pneumocystis Pneumonia Immune Modulate Agent Adverse Immunological Consequence
Unable to display preview. Download preview PDF.
- 1.B. Safai, R. A. Good, Kaposi’s sarcoma: A review in recent developments. Clin Bulletin 10: 62–69 (1980).Google Scholar
- 3.K. B. Hymes, T. Cheung, J. B. Green, Kaposi’s sarcoma in homosexual men. Report of 8 cases, Lancet i i: 598–600 (Sept. 1981).Google Scholar
- 4.R. Kriegel, L. Laubenstein, F. Muggia, Kaposi’s sarcoma: A new staging classification. Cancer Treatment Reports 67: 531–534 (1983).Google Scholar
- 5.P. Volberding, K. Kaslo, M. Bilk, Prognostic factors in staging Kaposi’s sarcoma in. the acquired immunodeficiency syndrome. Proceedings American Society of Clinical Oncology, p 19, (1984).Google Scholar
- 11.K. Welte, N. Ciobanun, G. Kruger, Impaired interleukin–2 production in response to PHA and OKT3 antibody in male homosexuals with acquired immunodeficiency syndrome: in vitro restoration of T-cell proliferation by highly purified interleukin–2, in: “AIDS, The Epidemic of Kaposi’s Sarcoma and Opportunistic Infections,” A. E. Friedman-Kien, L. J. Laubenstein, Masson Publishing U.S.A. Inc., New York, 199–205, (1983).Google Scholar